Sage's very exciting Chinese client, Guangzhou Doublle Bio-Product Co., Ltd., will report the results of its Chinese Phase 3 study of its Adenolysin, a biological for the treatment of late-stage head neck not including nasopharyngeal cancer, by the end of this year. Guangzhou Doublle seeks a development and commercialization partner for global or regional rights to Adenolysin outside China. In the late 1990s as a result of work done by Judah Folkman at the Sydney Farber Insti
Innovative Biological R&D in Microgravity Environments A Free Webinar You Should Not Miss! We learned of Axiom Space (Axiom Space - World’s First Commercial Space Station) during the BIO 2021 meeting, and are excited to offer the opportunity for you and your colleagues to learn about Axiom Space and how it might augment your R&D efforts in the future. The Sage Group are sponsoring a free webinar at 11 AM Eastern time on November 30 of this year.
Register Now! or email us a